Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1555)	12/19/2003 12:45:46 AM
From: scaram(o)uche	Respond to of 1784

from the '99 10-K.......... ITEM 1. BUSINESS Pharmacopeia, Inc. ("Pharmacopeia" or the "Company") offers products and services to accelerate drug discovery and chemicals development integrating three platform technologies: small molecule combinatorial chemistry, high-throughput screening, and simulations software. The Company's small molecule combinatorial chemistry and high-throughput screening operations are focused primarily on drug discovery and are conducted by its Laboratory Services segment ("Pharmacopeia Labs"). Through its wholly-owned subsidiary, Molecular Simulations Incorporated ("MSI"), which the Company acquired in 1998, Pharmacopeia's software segment develops and commercializes molecular modeling, simulation, and informatics software and services for both life science and materials science customers. I am not going to go back and did it up, but I'm certain that the PR extolled the benefits of combining software and drug discovery.